Neonatal Jaundice

Last updated: April 1, 2026

Overview

Neonatal jaundice refers to yellowness of the skin and mucous membranes due to elevated bilirubin within the first 28 days of life.

Ill-appearing babies with jaundice are more likely to have infections or metabolic disorders.

Well-appearing babies are more likely to have biliary atresia or anomalies of the biliary tree

Overview of causes of jaundice

ClassificationExamples
Increased productionHemolysis, cephalohematoma, bruising
Reduced clearanceGenetic mutations, prematurity, medications, hypothyroidism, metabolic conditions
Increased uptakeBreastfeeding failure jaundice, breast milk jaundice

Causes of indirect or unconjugated hyperbilirubinaemia

CategoryLaboratoryCauses
Autoimmune hemolysisCoombs positive + ReticulocytosisABO incompatibility, Rh isoimmunization
Non-autoimmune hemolysisCoombs negative + reticulocytosisHemoglobinopathies (spherocytosis, elliptocytosis), enzymatic deficiencies (G6PD deficiency, pyruvate kinase deficiency, hexokinase deficiency)
Non-autoimmune non-hemolytic (coombs negative, no reticulocyosis)Coombs negative + no reticulocytosisNeonatal sepsis, shock-liver (due to birth asphyxia), hepatitis, intrauterine infections (TORCHES), extravascular hemorrhage (e.g., cephalohematoma), twin-to-twin transfusion syndrome, maternal-fetal transfusion, infant of diabetic mother, Crigler-Najjar syndrome, Gilbert’s syndrome, exaggerated enterohepatic circulation (in breastfeeding jaundice, also consider ileus), breast-milk jaundice, polycythemia (infant of diabetic mother)

Causes of conjugated or direct hyperbilirubinaemia

ClassificationCauses
IntrahepaticViral hepatitis (CMV, enteroviruses, HSV, etc.), Bacterial hepatitis (E. coli, T. pallidum, L.monocytogenes), Disorders of metabolism (tyrosemia, fructose intolerance, galactosaemia, etc.), Genetic disorders (cystic fibrosis, A1AT-deficiency, PF1C, Rotor, Dubin-Johnson, etc.), Endocrine disorders (hypothyroidism, hypopituitarism), paucity of interlobular bile ducts, autoimmune hepatitis
ExtrahepaticBiliary atresia, choledochal cyst, Caroli’s disease, Alagille syndrome, Inspissated bile, Cystic fibrosis
  • Bilirubin metabolism
    • Heme degradation: 80% of heme comes from senescent RBCs, and 20% comes from other heme-containing proteins. Heme oxygenase converts heme → biliverdin (releasing Fe2+ and CO). Biliverdin reductase converts biliverdin → unconjugated bilirubin (lipophilic and insoluble). Bilirubin binds to albumin for transport to the liver
    • Hepatic uptake: Unconjugated bilirubin is hepatocytes is bound by ligandins intracellulary preventing its efflux back into plasma. Ligandins also facilitate bilirubin’s transport to the smooth endoplasmic reticulum for conjugation
    • Conjugation in the liver (glucuronidation): bilirubin is conjugated with glucuronic acid by UDP-glucuronosyltransferase (UGT1A1). It is converted into a hydrophilic form, enabling biliary excretion
    • Biliary excretion into the gut: Conjugated bilirubin is actively secreted in bile via multidrug resistance-associated protein 2 (MRP2). Bile is stored in the gallbladder and released into the duodenum after food intake
    • Intestinal fate: Bacteria metabolise bilirubin into urobilinogen (colorless). Some urobilinogen is reabsorbed via enterohepatic circulation and returned to the liver. The remainder is oxidized to stercobilin (brown pigment excreted in feces) and urobilin (yellow pigment excreted in urine)
    • Enterohepatic circulation: gut flora is usually immature in neonates, leading to increased enterohepatic circulation of bilirubin**. B-glucuronidase in the intestines deconjugates bilirubin, allowing it to be reabsorbed and contribute to physiologic jaundice.
  • Initial investigations
    • Complete Blood Count and Reticulocyte count to determine whether there is haemolysis or infection
    • Serum bilirubin: elevated in jaundice
    • Direct Coomb’s test: is hemolysis immune-mediated (isoimmunization)
    • LFTs
    • Albumin: hypoalbuminaemia lowers the threshold for bilirubin toxicity
    • TSH: for hypothyroidism
    • PT and aPTT
    • Inflammatory markers (pro-calcitonin, CRP)
  • Other investigations for hyperbilirubinemia based on history and physical exam findings
    • Abdominal sonography
    • TORCH titres – including Hepatitis B, urine for CMV
    • Cultures – blood, urine, CSF, and nasopharyngeal
    • HIDA scan
    • ERCP/MRCP
    • Percutaneous liver biopsy
    • Other tests: urine for reducing sugars, succinylacetone, and serum ferritin

Physiological jaundice

Most neonates will have some degree of physiologic jaundice (60-80%) – some yellow discolouration of the sclera may only be visible. This happens as the neonate transitions from reliance on the placenta to clear bilirubin onto the baby’s own hepatic system. Neonates also have a high hematocrit (of around 60%) and a lower RBC lifespan, which results in a high turnover.

Jaundice progresses from head to toe.

Characteristics of physiologic jaundice:

  • NEVER visible on the first day of life
  • TSB may rise to 5mg/dL per day until day 3-5
  • Conjugated bilirubin never passes 2 mg/dL OR 20% of TSB (whichever is lower)
  • TSB peaks around day 3-5
  • Visible jaundice resolves by 1 week of age (7 days) in a full-term AND 2 weeks (14 days) in a premature infant (< 37 weeks gestation)

Characteristics that predispose newborns to develop physiologic jaundice

CharacteristicDescription
Increased production of bilirubinNewborns have more RBCs with a shorter lifespan
Decreased clearance of bilirubinNewborns have immature liver enzymes
Increased uptakeNewborns have more enterohepatic circulation

Pathologic Jaundice

Pathologic jaundice is any jaundice that does not satisfy the criteria for physiologic jaundice AND has other symptoms of illness, such as difficulty feeding.

Characteristics of pathological jaundice:

  • Visible jaundice on the first day of life
  • TSB rapidly rises by 5mg/dL over a 24 hr period
  • Conjugated bilirubin surpasses 2 mg/dL or 20% TSB (whichever is lower)
  • TSB continues to rise after day 5
Reference Intervals
Biochemistry
ACTHP: <80 ng/L
ALTP: 5–35 U/L
AlbuminP: 35–50 g/L
AldosteroneP: 100–500 pmol/L
Alk. phosphataseP: 30–130 U/L
α-AmylaseP: 0–180 IU/dL
α-FetoproteinS: <10 kU/L
Angiotensin IIP: 5–35 pmol/L
ADHP: 0.9–4.6 pmol/L
ASTP: 5–35 U/L
BicarbonateP: 24–30 mmol/L
BilirubinP: 3–17 μmol/L
BNPP: <50 ng/L
CRPP: <10 mg/L
CalcitoninP: <0.1 mcg/L
Calcium (ionized)P: 1.0–1.25 mmol/L
Calcium (total)P: 2.12–2.60 mmol/L
ChlorideP: 95–105 mmol/L
CholesterolP: <5.0 mmol/L
VLDLP: 0.128–0.645 mmol/L
LDLP: <2.0 mmol/L
HDLP: 0.9–1.93 mmol/L
Cortisol AMP: 450–700 nmol/L
Cortisol MidnightP: 80–280 nmol/L
CK ♂P: 25–195 U/L
CK ♀P: 25–170 U/L
CreatinineP: 70–100 μmol/L
FerritinP: 12–200 mcg/L
FolateS: 2.1 mcg/L
FSHP: 2–8 U/L ♂; >25 menopause
GGT ♂P: 11–51 U/L
GGT ♀P: 7–33 U/L
Glucose (fasting)P: 3.5–5.5 mmol/L
Growth hormoneP: <20 mu/L
HbA1C (DCCT)B: 4–6%
HbA1C (IFCC)B: 20–42 mmol/mol
Iron ♂S: 14–31 μmol/L
Iron ♀S: 11–30 μmol/L
Lactate (venous)P: 0.6–2.4 mmol/L
Lactate (arterial)P: 0.6–1.8 mmol/L
LDHP: 70–250 U/L
LHP: 3–16 U/L
MagnesiumP: 0.75–1.05 mmol/L
OsmolalityP: 278–305 mosmol/kg
PTHP: 0.8–8.5 pmol/L
PotassiumP: 3.5–5.3 mmol/L
Prolactin ♂P: <450 U/L
Prolactin ♀P: <600 U/L
PSAP: 0–4 mcg/mL
Protein (total)P: 60–80 g/L
Red cell folateB: 0.36–1.44 μmol/L
Renin (erect)P: 2.8–4.5 pmol/mL/h
Renin (recumbent)P: 1.1–2.7 pmol/mL/h
SodiumP: 135–145 mmol/L
TBGP: 7–17 mg/L
TSHP: 0.5–4.2 mU/L
T4P: 70–140 nmol/L
Free T4P: 9–22 pmol/L
TIBCS: 54–75 μmol/L
TriglyceridesP: 0.50–2.3 mmol/L
T3P: 1.2–3.0 nmol/L
Troponin TP: <0.1 mcg/L
Urate ♂P: 210–480 μmol/L
Urate ♀P: 150–390 μmol/L
UreaP: 2.5–6.7 mmol/L
Vitamin B12S: 0.13–0.68 nmol/L
Vitamin DS: 50 nmol/L
Arterial Blood Gases
pH7.35–7.45
PaCO₂4.7–6.0 kPa
PaO₂>10.6 kPa
Base excess±2 mmol/L
Urine
Cortisol (free)<280 nmol/24h
Hydroxyindole acetic acid16–73 μmol/24h
Hydroxymethylmandelic acid16–48 μmol/24h
Metanephrines0.03–0.69 μmol/mmol cr.
Osmolality350–1000 mosmol/kg
17-Oxogenic steroids ♂28–30 μmol/24h
17-Oxogenic steroids ♀21–66 μmol/24h
17-Oxosteroids ♂17–76 μmol/24h
17-Oxosteroids ♀14–59 μmol/24h
Phosphate (inorganic)15–50 mmol/24h
Potassium14–120 mmol/24h
Protein<150 mg/24h
Protein/creatinine ratio<3 mg/mmol
Sodium100–250 mmol/24h
Haematology
WCC4.0–11.0 ×10⁹/L
RBC ♂4.5–6.5 ×10¹²/L
RBC ♀3.9–5.6 ×10¹²/L
Hb ♂130–180 g/L
Hb ♀115–160 g/L
PCV ♂0.4–0.54 L/L
PCV ♀0.37–0.47 L/L
MCV76–96 fL
MCH27–32 pg
MCHC300–360 g/L
RDW11.6–14.6%
Neutrophils2.0–7.5 ×10⁹/L (40–75%)
Lymphocytes1.0–4.5 ×10⁹/L (20–45%)
Eosinophils0.04–0.44 ×10⁹/L (1–6%)
Basophils0–0.10 ×10⁹/L (0–1%)
Monocytes0.2–0.8 ×10⁹/L (2–10%)
Platelets150–400 ×10⁹/L
Reticulocytes0.8–2.0% / 25–100 ×10⁹/L
Prothrombin time10–14 s
APTT35–45 s
Paediatric
Pulse Rate (bpm)
Neonate140–160
Infant <1yr120–140
1–5 years110–130
5–12 years80–120
>12 years70–100
Respiratory Rate (tachypnoea)
0–2 months≥60/min
2–12 months≥50/min
1–5 years≥40/min
>5 years≥30/min
Blood Pressure (mmHg)
Term65/45
1 year75/50
4 years85/60
8 years95/65
10 years100/70
Weight Formulas
3–12 months(a + 9)/2 kg
1–6 years2a + 8 kg
>6 years(7a − 5)/2 kg
Haemoglobin (g/dL)
Term newborn13–20
1 month11–18
2 months10–15
1–2 years10–13
>2 years11–14
MUAC (6 months–5 years)
Obese>17.5 cm
Normal13.5–17.4 cm
At risk12.5–13.4 cm
Moderate malnutrition11.5–12.4 cm
Severe malnutrition<11.5 cm
Developmental Milestones
Social smile1.5 months
Head control4 months
Sits unsupported7 months
Crawls10 months
Stands unsupported10–12 months
Walks12–13 months
Talks18 months
CSF WBC (/mm³)
Term newborn0–25
>2 weeks0–5
Calculator

Post Discussion

Your email address will not be published. Required fields are marked *